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Introduction
HIFs are transcription factors composed of 1 of 3 α chains (HIF1α, 
HIF2α, and HIF3α) dimerized to a β chain that mediates the tran-
scriptional response to low oxygen tension (hypoxia). These HIF 
isoforms transduce different components of the hypoxia response, 
with HIF1α and HIF2α being the most widely expressed and best 
understood. In the presence of oxygen, HIFα proteins are hydrox-
ylated by prolyl hydroxylase domain (PHD) enzymes, leading to 
their recognition and destruction by the von Hippel–Lindau (VHL) 
E3 ubiquitin ligase/proteasome pathway (1–4). Three closely relat-
ed PHD enzymes have been identified: PHD1, PHD2 and PHD3, 
with PHD2 being the most ubiquitous and important regulator 
of HIF levels. Inhibition of PHD enzyme activity by low oxygen 
levels or other means leads to HIF activation. Together, the dif-
ferent HIF isoforms activate a wide range of transcriptional tar-
gets with established effects on angiogenesis, erythropoiesis, and 
metabolism (1–4). It is increasingly clear that the HIF pathway also 
influences a number of other processes less directly related to oxy-
gen homeostasis (5, 6). Immune and inflammatory pathways are 
of particular interest because of their central importance in dis-
ease. HIFs are widely expressed in leukocytes and in different set-
tings have been reported to affect cell differentiation, migration, 
metabolism, growth, and apoptosis (7), as well as mediate changes 
in barrier function (8). Oxygen levels vary across tissues in health 
(9), and in inflamed tissues, hypoxia is generated by a combina-
tion of reduced oxygen availability, increased metabolic demands 
of rapidly dividing and migrating leukocytes, and specific oxy-
gen-consuming processes such as the respiratory (oxidative) burst 
(7). The effects of HIF pathway activation on immune and inflam-
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shRNA cassette (TRE-shRNA) bearing the relevant shRNA 
sequence downstream of the collagen type I α 1 (Col1a1) gene, 
were generated using recombinase-mediated cassette exchange 
(RMCE) (35). Efficacy in this context was confirmed by culturing 
the cells on gelatin in the presence of doxycycline prior to assess-
ment of the effects on target gene mRNA and protein levels, as well 
as on downstream transcription (Supplemental Table 1 and Supple-
mental Figure 1B). Following validation, we used ES cell clones to 
generate transgenic mice by blastocyst injection. Pure lines were 
then derived from the resultant chimeras and backcrossed with 
WT C57BL/6 mice for at least 6 generations prior to use.
Using these mice, we examined the consequences of sustained 
Phd2 KD in adult mouse tissues by initiating Phd2 silencing in 7- 
to 12-week-old mice. In order to increase the efficiency of Phd2 
silencing, we generated shPhd2#9 and shPhd2#3 mice by crossing 
the respective TRE-Phd2 alleles with mice harboring a transgene 
encoded at the GT(ROSA)26Sor locus that utilizes the strong exog-
enous CMV early enhancer element and chicken β-actin (CAG) 
promoter to express a third-generation reverse tetracycline- 
regulated transactivator gene (CAG-rtTA3). This produces stron-
ger and more ubiquitous target gene KD than does R26-rtTA (35). 
Following treatment with doxycycline, these inducible shPhd2#9 
mice showed widespread expression of GFP translated from the 
targeting sequence in all organs examined when viewed at the 
whole tissue level (Supplemental Figure 1C). Reverse transcrip-
tion PCR (RT-PCR) analysis showed that the shRNA sequence in 
these mice was effective at knocking down Phd2 mRNA levels in 
all tissues (Supplemental Figure 1D). Although the effect varied 
somewhat between tissues, in all cases, the degree of Phd2 KD 
was sufficient to result in upregulation of Phd3 and Bnip3, two 
HIF target genes, but had no consistent effect on Actb (a gene 
not considered to be a HIF target) (Supplemental Figure 1D). In 
keeping with these results, we performed immunoblotting of liver 
extracts from doxycycline-treated shPhd2#9 mice, which revealed 
a reduction in PHD2 protein levels and stabilization of HIF1α and 
HIF2α proteins (Supplemental Figure 1E). When doxycycline was 
removed, expression of GFP disappeared, and Phd2 mRNA levels 
normalized over a 2-week period (Supplemental Figure 1F). We 
obtained equivalent results with the shPhd2#3 mice. Overall, the 
shPhd2 mice we generated showed an effective but reversible KD 
of Phd2 mRNA across many tissues that was sufficient to stabilize 
and activate HIF and induce its target genes.
Long-term Phd2 KD results in widespread leukocytosis and 
immune pathology. On treatment for 5 to 8 weeks with doxycycline, 
shPhd2#9 mice became unwell, with weight loss, mild alopecia, 
and greasiness of the remaining hair (Figure 1A). Control mice 
bearing the CAG-rtTA but not the tetracycline-responsive element 
TRE-Phd2 shRNA allele remained healthy with doxycycline treat-
ment. We were surprised to find that shPhd2#9 mice were ane-
mic (hematocrit 36%–38% compared with control levels of 51% 
to 55%) and had gross peripheral lymphadenopathy and spleno-
megaly (Figure 1, B and C), although the mesenteric lymph nodes 
(LNs) appeared macroscopically unremarkable.
Histological examination confirmed the expansion of lym-
phoid tissues with distortion of the normal architecture but lack-
ing features suggestive of neoplastic transformation (Figure 1D). 
Eosinophilic mononuclear cells were prominent, expanding the 
matory pathways are therefore now of major medical importance, 
first, because tissue hypoxia complicates most human diseases 
(10) and, second, because drugs that target this pathway are now 
being tested in clinical trials (11).
Several studies have attempted to define physiological or 
pathological activities of the HIF/PHD system using genetic inac-
tivation. At the level of the whole animal, germline disruption of 
Phd2 results in developmental defects and embryonic lethality, 
whereas conditional knockout (KO) of Phd2 induced systemically 
in adult animals leads to increased angiogenesis, erythrocytosis, 
and changes in energy metabolism with ultimately lethal conse-
quences (12–15). Effects on the immune system from such global 
interventions have not been reported to date, perhaps because 
they have been obscured by these other phenotypes. In con-
trast, several studies have assessed the effects of targeting HIF/
PHD pathway components in individual leukocyte subsets. For 
instance, major effects of HIF1α on innate cells, CD4+ and CD8+ T 
cells, Th17 cells, and Tregs have been reported (16–34). Although 
these experiments have undoubtedly revealed an important role 
of the HIF/PHD system in immune function, the results reported 
have not always been congruent. Differences potentially arise, 
because experiments that use lineage-specific, promoter-driven 
KO models (in which genetic changes are activated only in spe-
cific cell populations at particular stages during development and 
cell differentiation) may fail to capture the complexity of natural 
immune cell interactions and run the risk of conflating adaptive 
physiology with developmental effects.
We chose to investigate the HIF pathway using inducible RNA 
interference gene knockdown (KD) in vivo. This offers the advan-
tages of timed and reversible specific gene silencing in mature 
cells, producing effects potentially more analogous to those which 
might occur physiologically, pathologically, or in response to phar-
macological inhibition. In this study, we investigated the effects of 
intervention on the major HIF hydroxylase PHD2, with and with-
out combined interventions on the 2 major HIF isoforms HIF1α 
and HIF2α. We show that KD of Phd2 mRNA in mice resulted in 
multilineage leukocytosis and immune dysregulation with fea-
tures of autoimmunity, events that were at least partially depen-
dent on changes in the behavior of cells bearing Treg markers. 
This phenotype was abrogated by simultaneous KD of Hif2a but 
not Hif1a mRNA.
Results
Inducible shRNA KD. To explore the consequences of HIF path-
way component suppression on normal mouse tissues, we devel-
oped transgenic inducible shRNA mice (Supplemental Figure 1A). 
Ten different shRNA sequences for Phd2 and 5 sequences each 
for Hif1a and Hif2a were tested initially for their effectiveness in 
reducing target gene mRNA levels following constitutive expres-
sion in mouse embryonic fibroblasts (MEFs) (Supplemental Table 
1). For each target, we selected the 2 sequences causing the great-
est percentage reduction in target gene mRNA levels for further 
study (Phd2#9 and Phd2#3; Hif1a#5 and Hif1a#1; and Hif2a#3 and 
Hif2a#1). KH2 mouse embryonic stem (ES) cells expressing both 
a reverse tetracycline transactivator (rtTA), driven by the endog-
enous GT(ROSA)26Sor promoter (R26-rtTA), and a single-copy 
tetracycline response element (TRE), controlled by the GFP- 
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empty hair follicles. Examination of other tissues revealed further 
changes, with striking perivascular accumulations of leukocytes in 
the bronchovascular regions of the lung (Figure 1M) and accumu-
lations in the kidney (Figure 1N) that were similar to those seen 
in some human autoimmune diseases. Further examination of the 
kidney showed an increase in glomerular size with endocapillary 
hypercellularity indicative of nephritis (Figure 1, O and P); there 
central regions of LNs and displacing cortical areas to the extreme 
periphery (Figure 1, D–G), and we observed similar changes in the 
splenic white pulp (Figure 1, H and I). Examination of the skin of the 
pinna showed thickening of both the epidermis and dermis, with 
loss of subcutaneous fat. We observed a diffuse lymphohistiocytic 
infiltrate within the dermis and evidence of exocytosis of lympho-
cytes into the epidermis (Figure 1, J–L). Elsewhere, we detected 
Figure 1. shPhd2#9 mice develop leukocyte expansion on doxycycline treatment. (A) Representative image of a shPhd2#9 mouse and its littermate 
control, both of which were treated with doxycycline (2 mg/mL with 30% sucrose drinking water ad libitum) for 4 to 5 weeks. (B) Representative bright-
field and GFP images of pLNs from a shPhd2#9 mouse and its littermate control. Scale bars: 1 cm. (C) Wet weight of pLNs (4 per mouse) and spleens 
(1 per mouse) from shPhd2#9 mice (n = 6) and their littermate controls (n = 6). Each symbol in C represents an individual mouse. Data are represented 
as the mean ± SEM. ***P < 0.001 and ****P < 0.0001. Unpaired, independent groups of 2 were analyzed by 2-tailed Student’s t test. (D–R) Images of 
H&E-stained tissues from shPhd2#9 and littermate control mice: pLN, original magnification, ×2.5 (D and E), ×10 (F), and ×80 (G) (arrows in G indicate 
cells with oval, vesicular nuclei and eosinophilic cytoplasm); spleen, original magnification, ×5 (H and I); skin, original magnification, ×20 (J and K) and 
×80 (L) (arrows in L point to exocytosis of lymphocytes into the epidermis); lung, original magnification, ×10 (M); kidney, original magnification, ×20 (N) 
and ×40 (O and P); liver, original magnification, ×40 (Q); and heart, original magnification, ×40 (R) (arrow in R indicates a focal collection of mononuclear 
inflammatory cells at the epicardial surface of the heart). Scale bars: 500 μm (original magnification, ×2.5, and proportionately shorter lengths at higher 
magnifications). Data are representative of 3 independent experiments at this time point.
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was no tubulointerstitial inflam-
mation. In the liver, steatosis 
was apparent, and we observed 
smaller collections of leuko-
cytes in both periportal and 
perivenous sites (Figure 1Q). 
We also found patchy infiltra-
tion by leukocytes in the epicar-
dium (Figure 1R) and scattered 
throughout skeletal muscle. 
Lymphoid aggregates can be 
seen as background changes in 
various organs in some mouse 
colonies, but in mice from this 
laboratory, we found that aggre-
gates were consistently more 
prominent in the shPhd2#9 
mice than in the control mice. 
Similar lymphadenopathy and 
splenomegaly with multilineage 
changes and comparable histo-
logical changes were observed 
with the shPhd2#3 mice that 
bore an independent sequence 
targeting Phd2 (Supplemental 
Figure 2).
In a subsequent experi-
ment, we monitored BW and 
hematological parameters over 
an 8-week period of Phd2 KD. 
Differences in BW of KD mice 
compared with that of con-
trol mice began to be apparent 
after 2 weeks and were pro-
gressive (Supplemental Figure 
3A). We observed the expected 
rise in red cell count over the 
first 2 weeks, but thereafter, 
the red cell count fell (Supple-
mental Figure 3B). There was 
a progressive rise in leukocyte 
counts throughout this period, 
and platelet counts were also 
higher in the shPhd2#9 mice 
than in the control animals 
(Supplemental Figure 3, C and 
D). Antinuclear antibodies 
(ANAs) could be detected in 
serum within the first 3 weeks 
of treatment.
Immunological effects 
observed in shPhd2 mice are 
multilineage and Hif2a isoform 
dependent. Flow cytomet-
ric analysis revealed that the 
lymphadenopathy was arising 
from effects across multiple 
Figure 2. Reduction of Hif2a expression reverses the phenotype in inducible Phd2-KD and Phd2-KO mice. (A) 
FACS analysis of cells from pLNs of shPhd2#9 (Phd2-KD), shPhd2Hif1 (Phd2-KD/Hif1a-KD), shPhd2Hif2 (Phd2-
KD/Hif2a-KD), and control mice for CD45, CD3, B220, and Gr1 expression. Mice were treated with doxycycline (2 
mg/mL with 30% sucrose drinking water ad libitum) for 4 weeks. Data from individual mice and the mean ± SEM 
are represented. *P < 0.05. Groups were compared by 1-way ANOVA with Tukey’s post hoc test. (B) Representative 
bright-field images (scale bar: 1 cm) and wet weight of pLNs from the same mice. Data are represented as the 
mean ± SEM. *P < 0.05 and ***P < 0.001. Multigroup comparisons were analyzed by a 1-way ANOVA with Tukey’s 
post-hoc test. (C) Mean BW changes (percentage relative to day 0) of the same mice during doxycycline treatment. 
Data are represented as the mean ± SD (n = at least 3 mice per group). Groups were compared by a repeated- 
measures ANOVA with Tukey’s multiple comparisons post hoc test: P < 0.001, control versus shPhd2#9;  
P < 0.01, control versus shPhd2Hif1; NS, control versus shPhd2Hif2; NS, shPhd2#9 versus shPhd2Hif1; P < 0.001, 
shPhd2#9 versus shPhd2Hif2; P < 0.001, shPhd2Hif2 versus shPhd2Hif1. (D) FACS analysis for CD45, CD3, B220, 
and Gr1 expression by cells in pLNs from conditional Phd2-KO, Phd2Hif1-KO (Phd2-KO/Hif1a-KO), Phd2Hif2-KO 
(Phd2-KO/Hif2a-KO), and control mice 4 weeks after tamoxifen treatment. Data from individual mice and the 
mean ± SEM are represented. Groups were compared by 1-way ANOVA with Tukey’s post hoc test. *P < 0.05,  
**P < 0.01, and ***P < 0.001. (E) Representative bright-field images (scale bar: 1 cm) and wet weight of pLNs from 
the same mice. Data are represented as the mean ± SEM. *P < 0.05 and **P < 0.01. Multigroup comparisons were 
analyzed by a 1-way ANOVA with Tukey’s multiple comparisons post hoc test. Each symbol in A–E represents an 
individual mouse. Data were consistent over 3 independent experiments.
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logical changes with Phd2 KD were abrogated with concomitant 
HIF2α but not HIF1α deficiency (Figure 3).
In summary, the major features of the shPhd2 phenotype 
include Hif2a-dependent lymphadenopathy, multilineage leukocy-
tosis, weight loss, ANA development, and immune-mediated organ 
pathology. These features were also seen in Phd2-KO animals.
Reversibility of the shPhd2 phenotype. We next explored the 
reversibility of the observed phenotype on reexpression of Phd2 
following doxycycline withdrawal. Groups of animals were treated 
with doxycycline for 3 to 4 weeks until the first members of each test 
cohort became unwell, as described above, triggering examination 
of tissues and serum from a randomly selected subset of the animals. 
The remaining animals were taken off doxycycline, their weight was 
monitored, and tissues and serum were subsequently examined. 
The animals treated with doxycycline lost weight, developed lymph-
adenopathy with expansion of all lineages, and their serum became 
positive for ANAs, with histological examination confirming the 
previously described changes (Figure 4). Following doxycycline 
withdrawal, the lymphadenopathy regressed (Figure 4A), the mice 
regained weight (Figure 4B), the ANAs disappeared (Figure 4C), and 
the histological and immunological features improved (Figure 4, 
D–L). This indicates that the changes observed in shPhd2 mice were 
reversible and not due to either a permanent change in cell pheno-
type or irrevocable loss of cells with a particular function.
The shPhd2 phenotype is transferrable by bone marrow trans-
plantation. The phenotype observed has many features sugges-
tive of autoimmune disease, but since the reduction of expression 
of Phd2 in these mice was systemic, it was unclear whether this 
phenotype could arise purely through effects on the immune sys-
tem. To test the role of the immune system in this phenotype, we 
next created bone marrow (BM) chimeras bearing shPhd2 BM in 
leukocyte lineages: total leukocytes, T cells, B cells, and myeloid 
lineages as defined by CD45, CD3, B220, and GR1 (Ly-6G/Ly-6C) 
positivity (Figure 2A and Supplemental Figure 4A). We next sought 
to determine whether these immunological effects were present in 
conditional Phd2-KO animals, although such effects were previous-
ly unreported. We examined mice bearing a tamoxifen-inducible 
Cre recombinase–expressing transgene (Rosa26CreERT2) and that 
were homozygous for floxed Phd2 alleles (RosaERTCre Phd2fl/fl) 4 
weeks after tamoxifen treatment. Peripheral lymphadenopathy was 
present in both the KD and KO mice (Figure 2, B and E), as was leu-
kocyte expansion (Figure 2, A and D).
Next, in order to assess whether the phenotype was depen-
dent specifically on the upregulation of either HIFα isoform, we 
developed double-KD and double-KO mice in which both Phd2 
and Hif1a or Hif2a were targeted. shPhd2Hif1 and shPhd2Hif2 
mice all carried one CAG-rtTA3 allele, one TRE-Phd2#9 allele, 
and a TRE-Hif allele targeting Hif1a or Hif2a, respectively. shPh-
d2Hif1 and shPhd2Hif2 mice were treated for 4 weeks with 
doxycycline at a dose of 2 mg/ml in the drinking water before 
analysis. The efficacy and specificity of Hif1a and Hif2a KD at 
the mRNA level in liver and spleen are shown in Supplemen-
tal Figure 5. Phd2Hif1-KO and Phd2Hif2-KO mice all carried 
one Rosa26CreERT2 allele and were homozygous for floxed Phd2 
alleles and homozygous for floxed alleles of Hif1a or Hif2a, 
respectively. Phd2Hif1-KO and Phd2Hif2-KO mice were exam-
ined 4 weeks after being treated with tamoxifen by gavage. The 
phenotype was reversed by concomitant Hif2a, KD, or KO in 
each model (Figure 2, B, C, and E). Additionally, expansion of all 
leukocyte lineages was completely ameliorated by concomitant 
HIF2α deficiency and partially reversed by concomitant HIF1α 
deficiency (Figure 2, A and D). Likewise, the inflammatory histo-
Figure 3. Concomitant Hif2a silenc-
ing ablates tissue inflammation in 
Phd2-KD mice. H&E-stained images 
of skin: original magnification, ×20; 
kidney: original magnification, ×10; 
and liver: original magnification, ×10 
(arrows demonstrate periportal and 
perivenous mononuclear inflamma-
tory cell infiltrates) from shPhd2#9 
(Phd2-KD), shPhd2Hif1 (Phd2-KD/ 
Hif1a-KD), shPhd2Hif2 (Phd2-KD/ 
Hif2a-KD), and control mice treated 
for 4 weeks with doxycycline. Scale 
bars: 125 μm (original magnification, 
×10, and proportionately shorter 
lengths at higher magnifications). 
Each column of images is represen-
tative of multiple sections from each 
organ from the same mouse. In this 
experiment, tissues from 2 mice of 
each genotype were examined.
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Figure 4. Phenotype reversal following withdrawal of doxycycline. (A) Representative bright-field images (scale bars: 1 cm) and wet weight of pLNs from 
shPhd2#9 mice and their littermate controls maintained on doxycycline for 3 to 4 weeks (doxycycline-ON group) or treated with doxycycline for 3 to 4 
weeks and then analyzed 7 weeks after doxycycline withdrawal (doxycycline ON/OFF group). Data are represented as the mean ± SEM (n = 4/group). ***P 
< 0.001. Multigroup comparisons were analyzed by 1-way ANOVA with Tukey’s multiple comparisons post hoc test. (B) Mean percentage of BW changes of 
shPhd2#9 and control mice, relative to day 0 of doxycycline treatment or doxycycline withdrawal. Data are represented as the mean ± SD (n = 7–8/group). 
****P < 0.0001, by 2-way ANOVA. (C) Representative fluorescence images of ANAs using mouse serum from doxycycline-ON and doxycycline-ON/OFF 
groups of shPhd2#9 and control mice. Scale bars: 50 μm. (D–K) H&E-stained images of (D and E) skin (original magnification, ×20); (F–I) kidney (original 
magnification, ×2.5 for F and G and ×10 for H and I); and (J and K) lung (original magnification, ×10) from doxycycline-ON and doxycycline-ON/OFF groups 
of shPhd2#9 mice. Scale bars: 500 μm (at ×2.5, and proportionately shorter lengths at higher magnifications). (L) FACS analysis of cells from pLNs from 
doxycycline-ON and doxycycline-ON/OFF groups of shPhd2#9 and control mice, analyzed for CD45, CD3, B220, and Gr1 expression. Data are represented 
as the mean ± SEM (n = at least 4/group). *P < 0.05. Unpaired, independent groups of 2 were analyzed by 2-tailed Student’s t test. Each symbol in A and L 
represents an individual mouse. Data were consistent over 2 independent experiments.
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the context of an otherwise normal animal. A congenic recipient 
strain (CD45.1) was used to confirm complete reconstitution with 
donor leukocytes. Control mice, generated in parallel, received 
BM from mice carrying the CAG-rtTA allele but not the TRE-
Phd2 shRNA–targeting sequence. BM transplantation (BMT) was 
performed, and the transplant was allowed to engraft for 8 weeks 
prior to treatment with doxycycline. Upon treatment with doxycy-
cline, mice that received KD BM (BMT-shPhd2#9), but not con-
trol BM (BMT-Ctrl), developed LN enlargement with multilineage 
expansion and detectable ANAs in their serum (Figure 5, A–C), 
although skin changes and tissue infiltration were less prominent 
than in the previous experiments (Figure 5, D–G). In both groups 
of animals, leukocytes in the peripheral blood were all of donor 
type (as defined by the Ptprca pan-leukocycte marker CD45.2) at 
the points of analysis. This indicates that when Phd2 KD is restrict-
ed to the BM, it is sufficient to generate the major features of the 
phenotype seen in shPhd2 mice.
Phd2 KD produces features of immune dysregulation. Taken 
together, these features suggested that the overall phenotype in 
shPhd2 mice was being driven at least in part by immune dysreg-
ulation. We therefore examined these mice for the presence of 
cells bearing T cell subset markers related to helper, effector, and 
regulatory functions. Examination of the expression of CD4 and 
CD8 revealed an increase in the absolute numbers of CD4+CD8– 
and CD4–CD8+ cells in LNs from shPhd2#9 mice compared with 
cells from control mice following 4 weeks of doxycycline treat-
ment (Figure 6A and Supplemental Figure 4B). Although the 
absolute numbers of these cell populations changed, their repre-
sentation when considered as a percentage of total CD3+ cells was 
relatively constant (Figure 6A). The absolute numbers of double- 
positive and double-negative cells remained low (Figure 6A and 
Supplemental Figure 6A). We next examined cells expressing 
CD25 and Foxp3, markers normally associated with Treg func-
tion, within the CD4+ cell population. Given the immune dysreg-
ulation in these mice, we were surprised to find that shPhd2 mice 
(with either targeting sequence) had increased absolute numbers 
of CD4+CD25+Foxp3+ T cells in peripheral LNs (pLNs) (Figure 
6B). Foxp3+ cells were also more abundant in the spleen and BM, 
although some of these cells no longer expressed CD25 (Supple-
mental Figure 6, B and C). We found that the relative abundance 
of Foxp3+ cells as a proportion of CD4+ T cell populations was 
also increased (Figure 6B and Supplemental Figure 6B). We also 
observed increased Foxp3+ counts in the LNs of recipients of KD 
but not control BM, indicating that it was a marrow-endogenous 
function and not a response to nonimmune abnormalities caused 
by widespread PHD2 deficiency (Figure 6C). The increase in 
Foxp3+ counts was reversible with doxycycline withdrawal (Fig-
ure 6D). In keeping with the overall phenotype, the increase in 
Figure 5. Transfer of the Phd2-KD 
phenotype by BMT. (A) Representative 
bright-field images (scale bar: 1 cm) and 
tissue weights of pLNs from mice that 
underwent BMT following 10 weeks 
of treatment with doxycycline (2 mg/
mL with 30% sucrose drinking water 
ad libitum). Syngeneic congenically 
marked (CD45.1) mice were lethally 
irradiated before receiving CD45.2 
shPhd2#9 BM (BMT-shPhd2#9; n = 6) 
or CD45.2 control BM (BMT-Ctrl; n = 2) 
and allowed to reconstitute for 8 weeks 
prior to doxycycline treatment. Data 
are represented as the mean ± SEM. 
(B) FACS analysis of cells in pLNs from 
BMT-Ctrl and BMT-shPhd2#9 mice, 
analyzed for CD45.2+, CD45.2+CD3+, 
CD45.2+CD19+, and CD45.2+Gr1+ expres-
sion. Data are represented as the mean 
± SEM. (C) Representative fluores-
cence images of ANAs using mouse 
serum from BM transplant recipients. 
Scale bars: 50 μm. (D–G) H&E-stained 
images of (D and E) pLNs (original mag-
nification, ×2.5) and (F and G) livers 
(original magnification, ×5) from BM 
transplant recipient mice. Arrows in F 
indicate inflammatory foci. Scale bars: 
500 μm (original magnification, ×2.5, 
and proportionately shorter lengths at 
higher magnifications). Each symbol 
in A and B represents an individual 
mouse. The same experiment was 
repeated independently twice.
The Journal of Clinical Investigation   R E S E A R C H  A R T I C L E
3 6 4 7jci.org   Volume 129   Number 9   September 2019
the spleens, of Phd2-KO animals (Figure 6F and Supplemental 
Figure 6D). The Treg-specific demethylated region (TSDR) was 
demethylated in Foxp3+ cells isolated from doxycycline-treated 
shPhd2 mice (Figure 6G).
the number of Foxp3+ cells was totally corrected by simultaneous 
Hif2a deficiency and partially reduced by Hif1a deficiency in the 
doxycycline-treated shPhd2 and Phd2-KO animals (Figure 6, E 
and F). We observed similar trends in the LNs and BM, but not 
Figure 6. Enumeration and TSDR analysis of cells bearing helper, effector, and regulatory markers in Phd2-KD and -KO mice. (A) Gating strategy and 
enumeration of single-positive (CD4+CD8– or CD4–CD8+), double-positive (CD4+CD8+), and double-negative (CD8–CD4–) cells within pLNs from control and 
shPhd2#9 mice following 4 weeks of doxycycline treatment (2 mg/mL with 30% sucrose drinking water ad libitum). **P < 0.01, by 2-tailed Student’s 
t test. (B) Expression of Foxp3 and CD25 within CD4+ cell populations within pLNs from control and shPhd2#9 mice following 4 weeks of doxycycline 
treatment. *P < 0.05, **P < 0.01, and ****P < 0.0001, by 2-tailed Student’s t test. (C) CD45.2+CD3+CD4+Foxp3+ cell numbers in pLNs from lethally irradiated 
syngeneic CD45.1+ congenically marked mice receiving BM transplants from CD45.2+ shPhd2#9 or CD45.2+ control mice. Data are represented as the mean ± 
SEM. (D) CD3+CD4+Foxp3+ cell numbers in the pLNs of shPhd2#9 mice and their littermate controls, treated with doxycycline for 3 to 4 weeks and analyzed 
directly (ON) or 7 weeks after doxycycline withdrawal (ON/OFF) (n = 7–8 in 2 independent assays). **P < 0.01, by 2-tailed Student’s t test. (E) CD3+CD4+ 
Foxp3+ cell numbers in pLNs from shPhd2#9 (Phd2-KD), shPhd2Hif1 (Phd2-KD/Hif1a-KD), shPhd2Hif2 (Phd2-KD/Hif2a-KD), and control mice. *P < 0.05, 
by 1-way ANOVA with Tukey’s multiple comparisons post hoc test. (F) CD3+CD4+Foxp3+ cell numbers in pLNs from Phd2-KO, Phd2Hif1-KO (Phd2-KO/Hif1a-
KO), Phd2Hif2-KO (Phd2-KO/Hif2a-KO), and control mice. Data are represented as the mean ± SEM. (G) Flow-sorted CD4+Foxp3+ or CD4+Foxp3– cells from 
control or shPhd2#9 mice that were treated for 4 weeks with doxycycline were analyzed by prosequencing for the percentage demethylation of their TSDR 
on the active X chromosome. Data are represented as the mean ± SEM (n = at least 3/group). Unpaired, independent groups of 2 were analyzed by 2-tailed 
Student’s t test. Multigroup comparisons were analyzed by 1-way ANOVA with Tukey’s or Dunnett’s multiple comparisons post hoc test. TSDR data were 
analyzed by 2-way ANOVA with Sidak’s correction for multiple comparisons. Each symbol represents an individual mouse. Data in C–G are representative 
of 2 independent experiments.
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WT C57BL/6 (H-2b) mice, either 
alone or in combination with 
shPhd2 or control CD4+CD25+ 
Tregs (expressing Foxp3 at >85% 
purity, using previously estab-
lished cell doses [ref. 36]) and 
subsequently received a skin 
transplant from a CBA (H-2k) 
donor. shPhd2 CD4+CD25+ cells 
were isolated from mice carrying 
both CAG-rtTA and TRE-Phd2 
shRNA alleles, whereas control 
CD4+CD25+ cells were isolated 
from mice carrying the CAG- 
rtTA allele alone. In initial exper-
iments, CD4+CD25+ cells were 
derived from donor animals pre-
treated with doxycycline to ensure 
that any change in function result-
ing from Phd2 KD had already 
developed (Figure 7B), and doxy-
cycline treatment was continued 
for the duration of the experiment 
after transplantation to ensure 
that Phd2 KD was maintained. In 
these experiments, we observed 
that CD4+CD25+ cells from dox-
ycycline-pretreated shRNA mice 
were unable to control skin rejec-
tion to the same degree that con-
trol CD4+CD25+ cells could.
In subsequent experiments, 
cells were obtained from mice of 
the same genotypes, but doxycy-
cline treatment was only started 
after adoptive transfer into the 
recipient mice to ensure that the 
effects of Phd2 KD were being 
tested on cell subsets that were 
identical at the point of transfer 
into the C57BL/6 (H-2b) Rag1–/– 
recipients. Again, in contrast to 
the CD4+CD25+ cells from mice 
carrying the CAG-rtTA allele 
alone, we found that shPhd2 
CD4+CD25+ cells were unable 
to control graft rejection (Fig-
ure 7C). In both assays, shPhd2 
CD4+CD25+ cells provided no 
quantifiable benefit to graft sur-
vival, with grafts being rejected at 
least as quickly as was seen in mice receiving effector cells alone, 
indicating a total loss of regulatory function in this in vivo model.
In parallel, in vitro experiments were performed to assess the 
ability of doxycycline-treated CD4+CD25+ cells, from the same 
sources, to suppress the proliferation of CD4+CD25–responder cells 
stimulated polyclonally with anti-CD3 and anti-CD28 beads or 
Given the paradox of increased numbers of cells bearing Treg 
markers in mice with an autoimmune phenotype, we next tested 
the function of these cells. We assessed the ability of CD4+CD25+ 
cells to regulate the activity of effector cells in skin allograft rejec-
tion in vivo (Figure 7A). Immunodeficient C57BL/6 (H-2b) Rag1–/– 
mice were reconstituted with CD4+CD25– effector T cells from 
Figure 7. Treg functional assays. (A) Schematic of in vivo experimental plan. C57BL/6 Rag1–/– (H-2b) mice received 
CD4+CD25– Teffs with or without H-2b CD4+CD25+ cells from shPhd2#9 or control mice that had received either 
1 week of doxycycline (2 mg/ml in drinking water, ad libitum) pretreatment or no doxycycline pretreatment. 
One day later, mice received an allogeneic H-2k skin graft. Mice receiving cells from doxycycline-treated donors 
remained on doxycycline (B), whereas those receiving cells from untreated donors started doxycycline treatment 
from day 2 after transplantation (C). Allograft survival was monitored until rejection. (B) Survival graph for mice 
that received adoptively transferred cells derived from mice pretreated for 1 week with doxycycline. Doxycycline 
exposure continued in the recipient mice. (C) Survival graph for mice that received adoptively transferred cells 
derived from untreated mice. The cells were only exposed to doxycycline after adoptive transfer when it was add-
ed to the drinking water of recipient mice. Survival data in B and C were analyzed by log-rank test. The number of 
animals in each group is indicated. (D) Schematic of in vitro experimental plan. Control C57BL/6 WT Teffs (1 × 105/
well) (CD4+CD25– responders [R]) were stimulated (S) with 1 × 105/well of anti-CD3 and anti-CD28 beads or 2 × 104 
CBA (H-2k) DCs. CD4+CD25+ cells from shPhd2#9 or control mice were added at 1:1, 1:2, 1:4, and 1:8 ratios relative 
to Teff responders. Doxycycline at 1 μg/mL was added to all wells and replenished daily. Cells were incubated for 
5 days, and 3H-thymidine was added for the final 18 hours of culture. Proliferation levels were normalized to the 
positive control (R + S). (E) In vitro suppression assay using anti-CD3 and anti-CD28 as stimulators. (F) In vitro 
suppression assay using DCs as stimulators. Data are represented as the mean ± SEM of biological replicates. 
Unpaired, independent groups (1:1, 1:2, 1:4, and 1:8) of 2 were analyzed by 2-tailed Student’s t test in E and F.  
*P < 0.05, **P < 0.01, and ****P < 0.0001.
The Journal of Clinical Investigation   R E S E A R C H  A R T I C L E
3 6 4 9jci.org   Volume 129   Number 9   September 2019
in CD4+Foxp3+ and CD4+Foxp3– 
cells from shPhd2 and control mice 
and found that in both populations, 
Phd2kd led to a reduction in cells 
with a CD44loCD62Lhi naive phe-
notype and an increase in CD44hi 
CD62Llo effector memory cells (Fig-
ure 10 and Supplemental Figure 8).
Discussion
Here, we report on a model for the 
genetic investigation of HIF/PHD 
hypoxia signaling pathways in the 
mouse as well as on the occurrence 
of a systemic autoimmune pheno-
type following suppression of the 
principal HIF prolyl hydroxylase 
PHD2. Following shRNA-mediated 
KD of Phd2, the mice developed a 
multilineage leukocyte expansion 
that was associated with destruc-
tion of lymphoid organ architec-
ture, immune infiltration of major 
organs, ANAs. In keeping with 
the stochastic nature of immune responses, this phenotype was 
somewhat variable between individual KD mice, but overall, the 
phenotype was transferrable by BMT and reversible when doxycy-
cline-driven, shRNA-mediated suppression of Phd2 was stopped.
These findings strongly suggested the occurrence of an auto-
immune syndrome but were somewhat surprising in view of early 
reports on general inactivation of Phd2 using conditionally acti-
vated Cre recombinase, which did not highlight such a phenotype. 
Nevertheless, near-identical phenotypes obtained using 2 distinct 
shRNAs and complete suppression by coincident shRNA-mediat-
ed KD of Hif2a strongly suggested that the phenotype reflected 
on-target actions of the interventions. We therefore reexamined 
the phenotype of Cre recombinase–mediated Phd2 inactivation in 
an additional set of mice. These experiments revealed a similar, 
though somewhat less severe, inflammatory phenotype associat-
ed with the development of ANAs, which was also suppressed by 
combined inactivation of Phd2 with Hif2a. Though it is possible 
that this phenotype was obscured in the earlier studies by other, 
ultimately fatal, consequences of Phd2 inactivation, we note that 
one of the earlier reports of Phd2-KO mice noted the occurrence 
of leukocytosis and thrombocytosis, such as we observed in the 
present study (14). Taken together, our findings indicate that Phd2 
KD or KO in adult mice has the potential to cause an autoimmune 
phenotype driven by cells originating within the BM.
It is unclear to us why this phenotype was generally stronger in 
the KD mice than in the KO animals, although we cannot exclude 
the possibility of a sensitizing effect of RNA interference or dox-
ycycline. However, no such effects have been described in multi-
ple reports of the use of the same doxycycline-inducible shRNA 
system to target other genes (37–40). Other important differences 
between the KD and KO systems could be relevant. In our expe-
rience, recombination between the loxP sites in the conditional 
Phd2-KO allele was always less than complete in any cell popu-
with allogeneic DCs (Figure 7D). In both assays (Figure 7, E and F, 
respectively), CD4+CD25+ cells from doxycycline-treated shPhd2 
animals were less effective at regulating the proliferative response 
than were cells from control animals. Taken together, the results 
of both in vivo and in vitro experiments indicate that CD4+CD25+ 
cells are hypofunctional as immune regulators when Phd2 levels 
are knocked down, suggesting that deficiency of Treg function may 
contribute to the autoimmune phenotype we observed.
Noting that skin graft rejection appeared slightly faster in the 
presence of CD4+CD25+ shPhd2 cells than when effector cells 
were present alone, we tested the ability of CD4+CD25+ shPhd2 
cells to reject a skin graft in isolation (Figure 8A). Intriguingly, cells 
selected with this surface phenotype prior to doxycycline treat-
ment and then adoptively transferred into Rag1–/– recipients were 
able to reject skin allografts when these mice were treated with 
doxycycline, whereas we observed long-term graft survival in the 
doxycycline-treated recipients of CD4+CD25+ cells from control 
mice (Figure 8B). This indicates that Phd2 KD may lead to a con-
verse effector function in this population of cells. Additionally, the 
shPhd2 recipient mice, but not those receiving control cells, devel-
oped features of the phenotype observed in shPhd2 mice, as these 
mice became unwell and lost weight, which led to early termina-
tion of the experiment for 1 animal. The loss of regulatory function 
and/or conversion to effector functionality can therefore induce 
the development of an autoimmune phenotype in shPhd2 mice.
To analyze the basis for these functional differences, we com-
pared the expression of key transcription factors and cytokines in 
CD4+Foxp3+ and CD4+Foxp3– cells from shPhd2 and control mice 
(Figure 9 and Supplemental Figure 7). We showed that despite 
ongoing expression of Foxp3, cells within this population from 
shPhd2 mice expressed increased levels of T-bet and TNF-α, but 
not IFN-γ, RORγt, GATA-3, IL-2, IL-4, IL-10, or IL-17. To take this 
analysis further, we examined the expression of CD44 and CD62L 
Figure 8. Phd2-KD CD4+CD25+ cells alone can induce skin allograft rejection. (A) Schematic of the in vivo 
experimental plan. C57BL/6 Rag1–/– (H-2b) mice received either 5 × 104 H-2b CD4+CD25+ cells from shPhd2#9 
mice; 5 × 104 H-2b CD4+CD25+ cells from control mice; or 5 × 104 H-2b WT CD4+CD25– effector cells alone. One 
day later, mice received an allogeneic H-2k skin graft, followed by doxycycline treatment (2 mg/ml in the 
drinking water, ad libitum) from day 2 after transplantation. Allograft survival was monitored until rejection. 
(B) Skin allograft survival graph. Allograft survival data were analyzed by log-rank test. The censored data 
point in the shPhd2#9 group represents a mouse that developed weight loss and a generalized inflammatory 
phenotype. **P < 0.01, by log-rank test.
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phenotype was reproducible across the 2 
models and therefore potentially relevant 
to both the physiology of immune reg-
ulation and the clinical development of 
PHD2 and HIF2α inhibitors.
Tregs, which express the forkhead 
box transcription factor Foxp3, are key 
to immune homeostasis, and their dis-
ruption results in pathology with a num-
ber of similarities to those we observed 
in shPhd2 mice. Scurfy mice have a dis-
abling mutation of Foxp3, which leads to 
a fatal lymphoproliferative disorder (41). 
Human mutations in the FOXP3 gene 
cause an X-linked syndrome (IPEX) char-
acterized by immune dysregulation, poly-
endocrinopathy, and enteropathy (42, 43). 
Although it is formally possible that the 
development of ANAs in our model was 
simply a consequence of the expansion 
of the total number of B cells, similarities 
in the lymphoid pathology of these con-
ditions to that observed in shPhd2 mice 
led us to further examine Tregs (shPhd2 
mouse cells bearing the Treg markers 
CD4+CD25+ and/or Foxp3+) from these 
mice. In contrast to most other models of 
immune dysregulation, we found that the 
absolute number of these Tregs in shPhd2 
mice was increased compared with that 
in controls and that their ratio relative to the cell populations they 
control was also increased in the LNs but not the spleen. Howev-
er, when equal numbers of cells were directly compared, the abil-
ity of Tregs (as defined by the expression of these markers) from 
shPhd2 animals to suppress either skin allograft rejection or in 
vitro responder T cell proliferation was impaired. The TSDR with-
in the Foxp3 locus of shPhd2-derived CD4+CD25+ cells remained 
demethylated. Since expression of Foxp3 is dependent on selec-
tive demethylation of the TSDR (44), this finding is consistent with 
lation within the Rosa-CreER–KO (Phd2-KO) mice that we used. 
Thus, it could be that residual, normal unrecombined cells were 
sufficient to significantly suppress the phenotype, whereas in 
the KD system, all cells would be expected to be affected by the 
shRNA expression, and thus no potentially compensatory normal 
cells would be present. It is equally possible that complete KO of 
Phd2 in certain cells leads to their deletion and hence a phenotype 
that is somewhat less severe. Whatever the explanation for these 
quantitative differences, the occurrence of a qualitatively similar 
Figure 9. Expression patterns of T cell–related  
cytokines and transcription factors in 
shPhd2#9 mice. (A) Representative flow 
cytometric plots showing expression of T-bet, 
TNF-α, IFN-γ, IL-4, GATA-3, IL-17, ROR-γt, IL-2, 
and IL-10 against Foxp3 within the total CD4+ 
cell populations from pLNs of control and 
shPhd2#9 mice following 4 weeks of doxycy-
cline treatment (2 mg/ml with 30% sucrose 
drinking water, ad libitum). (B) Percentage 
of cells expressing T-bet, TNF-α, IFN-γ, IL-4, 
GATA-3, IL-17, ROR-γt, IL-2, and IL-10 within 
CD4+Foxp3– or CD4+FoxP3+ cell populations 
from pLNs of control and shPhd2#9 mice after 
4 weeks of doxycycline treatment (n = 6 mice 
per group). Data are represented as the mean 
± SEM. *P < 0.05, **P < 0.01, ***P < 0.001, by 
2-tailed Student’s t test.
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or inflammatory cytokines such as IL-1β and IL-6 (56–58). Local 
tissue hypoxia is an established consequence of inflammation, and 
our results suggest a mechanism by which, in this setting, hypoxia 
may provide an additional cue for Tregs to modify their behavior 
and assist in the potentiation of required immune responses.
Inhibitors of PHD2 are now undergoing late-phase clinical 
trials for the treatment of anemia in patients with kidney disease 
(59). In this setting, very low intermittent dosing schedules are 
used in an attempt to specifically target erythropoietin produc-
tion in the diseased kidneys and liver. This contrasts with our 
use of high-dose doxycycline and widely expressed transgene 
promoters to knock down or knock out PHD2, so that it is unlike-
ly that exposures to the interventions are equivalent. In prelimi-
nary studies using short-term (≤72 hours) treatment of isolated 
cells, we did not observe consistent effects of prolyl hydroxylase 
inhibitors on human Tregs. Nevertheless, we believe that our 
findings are important. Interestingly, the antihypertensive agent 
hydralazine has inhibitory action against the HIF hydroxylases 
(60) and causes “drug-induced” systemic lupus erythematosus 
in a dose-dependent manner (61). Importantly, the syndrome we 
describe and hydralazine-induced lupus are both reversible. Thus, 
attempts to enhance immunity by PHD2 inhibition in specific set-
tings might be a clinically credible strategy meriting assessment 
in future studies. Our finding that the autoimmune syndrome was 
suppressed by concurrent KD of Hif2a also suggests that the new-
ly developed HIF2α antagonists, currently in clinical trials for the 
treatment of renal cancer (62), might be assessed in autoimmu-
nity and transplantation. Overall, our newly developed model for 
reversible intervention on the HIF/PHD system and the findings 
we believe to be novel on the dysregulation of immune function 
should be of interest as this emerging area of medicine is explored.
Methods
Constructs and shRNAs. miR30-based shRNA–targeting vectors were 
subcloned as previously described (35, 63). To identify potent shRNAs 
targeting murine Phd2, ten different 97-bp oligonucleotides predicted 
from shRNA design algorithms (35) were XhoI-EcoRI subcloned into 
the miR-30 cassette of the pGIPZ vector and screened by quantita-
tive PCR (RT-PCR) for effects on mRNA levels in MEFs. Sequences 
were introduced into MEFs by lentiviral infection, and after 48 hours 
of doxycycline (doxycycline; doxycycline hyclate) treatment (2 μg/
ml), target gene mRNA levels were measured and normalized against 
Actb, and the percentage of KD in transgenic cells was compared with 
the maintained expression of Foxp3 we observed. Furthermore, 
the absence of epigenetic changes is consistent with the reversible 
nature of the phenotype upon doxycycline withdrawal in shPhd2 
mice, which is relatively rapid in relation to the normal lifespan 
of Tregs. Phenotypically, these cells increased their expression 
of T-bet and TNF-α and gained a CD44hiCD62Llo effector mem-
ory phenotype, but did not manifest features of Th17 conversion. 
Taken together, these results suggest that there is a functional 
switch downstream of, or independent from, Foxp3. However, this 
change was not simply a loss of regulatory function, since shPhd2 
KD, induced after cells expressing Treg markers were transferred 
into an immunodeficient recipient, resulted in cells being present 
that acted positively to cause skin allograft rejection in the absence 
of any other effector cell population, indicating that a functional 
inversion had occurred within the transferred cell population.
Several studies have reported abnormalities in lymphocyte 
differentiation following genetic interventions on HIF or its reg-
ulatory machinery, in specific subsets of lymphocytes (16–31, 33). 
These phenotypes include abnormalities of Tregs in some stud-
ies, but the results were not always concordant and differ from 
our current findings. For instance, inactivation of Vhl, the gene 
encoding the ubiquitin E3 ligase that targets hydroxylated HIFα 
polypeptides for proteasomal destruction, using Cre recom-
binase restricted by a Foxp3 promoter, resulted in a reduction 
of Foxp3 expression and an inflammatory phenotype that was 
dependent on HIF1α (29).
Our studies in the new model are the first to our knowledge to 
interrogate T cell function in the setting of general inactivation of 
Phd2, a difference that is probably important in view of the poten-
tial for crosstalk between subsets of lymphocytes. The observa-
tion of cells bearing classical Treg markers, which were apparently 
hypofunctional in immune suppression, or even stimulatory, is 
unusual. Nevertheless the results are consistent with emerg-
ing data on functional heterogeneity in Tregs. For instance, it is 
increasingly clear that Foxp3 alone does not ensure stability of the 
suppressive function of Tregs (45, 46). A number of additional fac-
tors are important for this function, including signaling through 
the T cell receptor (TCR) and CD25 (47, 48) and other signaling 
pathways, such as Nrp1 (33, 49), Foxo1/3a (50), and Eos (51). Fur-
thermore, the multifunctional potential of Tregs is increasingly 
thought to be required physiologically for specific responses that 
are dependent on microenvironmental cues (46, 52–55). Environ-
mental cues identified to date include the presence of TLR ligands 
Figure 10. Identification of naive and memory T cells in shPhd2#9 mice. Dot plots and quantification of naive (TN) (CD44loCD62Lhi), central memory (TCM) 
(CD44hiCD62Lhi) and effector memory (TEM) (CD44
hiCD62Llo) T cells within pLNs of control and shPhd2#9 mice following 4 weeks of doxycycline treatment 
(2 mg/ml with 30% sucrose drinking water, ad libitum) (n = 6 mice per group). Data are represented as the mean ± SEM. *P < 0.05 and ****P < 0.0001, by 
2-tailed Student’s t test.
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provided ad libitum, and the animals were maintained on a 12-hour 
light/12-hour dark cycle. After the preliminary experiments, pheno-
typing experiments were blinded and randomized as indicated, and 
no animals were excluded from the study.
Characterization of transgenic shRNA mice. Following fixation with 
fresh 10% neutral buffered formalin, GFP expression was assessed by 
bright-field imaging of tissues obtained from CAG-rtTA–driven Phd2-
KD shRNA mice treated with doxycycline (2 mg/ml drinking water 
with 30% sucrose ad libitum) for the duration indicated in the figure 
legends. Images were acquired using an image scanner (ChemiDoc 
XRS+ System with ImageLab Software, Bio-Rad Laboratories).
Hematological analysis. Mice were culled, and blood obtained 
from the inferior vena cava or heart was collected into heparin- 
prefilled tubes. Blood samples were immediately analyzed using a Sys-
mex KX-21N Automated Hematology Analyzer.
ANA tests. Mouse serum samples were diluted 10 times and add-
ed to slides precoated with human epithelial HEp-2 cells (Fluores-
cent ANA Test System, Immuno Concepts). These were then stained 
with a goat anti–mouse IgG Alexa Fluor 488 secondary antibody 
(Invitrogen, Thermo Fisher Scientific), diluted 1:500 in PBS. Fluo-
rescent images were acquired using a fluorescence stereomicroscope 
as described previously (65).
Expression analysis. RNA was extracted from several mouse tissues 
using a TRI Reagent Kit (MilliporeSigma) or an RNeasy Kit (QIAGEN). 
Purified total RNA (0.5–1.0 μg) was reverse transcribed using an RT-PCR 
kit (High Capacity cDNA Reverse Transcription Kit, Applied Biosyste-
ms, Thermo Fisher Scientific). mRNA expression was determined by 
RT-PCR (Platinum SYBR Green, Invitrogen, Thermo Fisher Scientific) 
using the primer pairs for Phd2 (forward, GCCCAGTTTGCTGACATT-
GAAC and reverse, CCCTCACACCTTTCTCACCTGTTAG); Hif1a 
(forward, TGCTCATCAGTTGCCACTTCC and reverse, CCATCT-
GTGCCTTCATCTCATCTTC); Hif2a/EPAS1 (forward, ACGGAG-
GTCTTCTATGAGTTGGC and reverse, GTTATCCATTTGCTGGTC-
GGC); Bnip3 (forward, GACGAAGTAGCTCCAAGAGTTCTCA and 
reverse, CTATTTCAGCTCTGTTGGTATCTTGTG); Phd3 (forward, 
TCAACTTCCTCCTGTCCCTCATC and reverse, GCGAACATA-
ACCTGTCCCATTTC); Actb (forward, CTAGGCACCAGGGTGTGAT 
and reverse, TGCCAGATCTTCTCCATGTC); Hprt (forward, GTTG-
GATACAGGCCAGACTTT and reverse, CCACAGGACTAGAACT-
GC); and Egfp (forward, TGCTCAGGTAGTGGTTGTCG and reverse, 
AGAACGGCATCAAGGTGAAC). Values were analyzed as the relative 
quantification (RQ = 2–ΔΔCt) against the expression levels of the house-
keeping gene Hprt or Actb by Step One Plus Real-Time PCR System 
(Applied Biosystems, Thermo Fisher Scientific).
Western blotting, flow cytometry, and antibodies. Western blotting 
was performed according to standard protocols in our laboratory 
(66). In brief, tissues were snap-frozen in liquid nitrogen and homog-
enized using a glass homogenizer on ice. Protein was extracted using 
a standard protein lysis buffer (10 mM Tris, pH 7.5, 1% SDS, 10% 
glycerol, 6.87 M urea) supplemented with a protease inhibitor cock-
tail (Complete, Roche Diagnostics) and quantified using a Pierce 
BCA Protein Assay Kit (Thermo Fisher Scientific). Proteins were sep-
arated on a polyacrylamide gel (Tris-glycine 8%–16% mini, NuSep 
Inc., Generon) and transferred onto a PVDF membrane (Immo-
bilon-P, 0.45 μm, MilliporeSigma). Primary antibodies used for 
Western blot analysis included those against PHD2 (NB100-2219, 
Novus Biologicals); HIF1α (NB100-479, Novus Biologicals); HIF2α 
control cells, which received an shRNA against Firefly luciferase (Sup-
plemental Table 1). For KD of murine Hif1a and Hif2a, five shRNAs 
against each target were designed and subcloned, and their KD levels 
were tested as described above.
ES cell targeting and generation of transgenic mice. The targeting 
and screening strategy for ES cell production followed the method 
described previously (35, 63). Two potent shRNAs against murine 
Phd2 (shPhd2#9 97-mer, 5′-TGCTGTTGACAGTGAGCGCCGCCA-
CAAGGTACGCAATAACTAGTGAAGCCACAGATGTAGTTATTG-
CGTACCTTGTGGCGTTGCCTACTGCCTCGGA-3′ and shPhd2#3 
97-mer, 5′-TGCTGTTGACAGTGAGCGCACGCAATAACTGTTTG-
GTATTTAGTGAAGCCACAGATGTAAATACCAAACAGTTATTGC-
GTATGCCTACTGCCTCGGA-3′) were subcloned into a cassette that 
links EGFP and shRNA expression downstream of a TRE and targeted 
by RMCE into a defined locus downstream of the Col1a1 gene in KH2 
ES cells, which also express the reverse transactivator rtTA from the 
Gt(ROSA)26Sor promoter (35, 63). Southern blotting demonstrated 
correct transgene insertion, and doxycycline-inducible KD of endoge-
nous Phd2 was confirmed by RT-PCR and immunoblot analysis. Germ-
line transgenic mice were generated using the standard blastocyst 
injection method. MEFs were generated from 13.5-day-old embryos 
according to standard protocols. A similar approach was adopted for the 
creation of KD mice targeting Hif1a and Hif2a (shHif1 and shHif2 mice, 
respectively) using the most efficient shRNAs identified in our prelim-
inary screening (shHif1a#5 97-mer, 5′-TGCTGTTGACAGTGAGC-
GAACGGGCCATATTCATGTCTATTAGTGAAGCCACAGATGTA-
ATAGACATGAATATGGCCCGTGTGCCTACTGCCTCGGA-3′ and 
shHif2a#3 97-mer, 5′-TGCTGTTGACAGTGAGCGAACACTTGAT-
GTGGAAACGTATTAGTGAAGCCACAGATGTAATACGTTTCCA-
CATCAAGTGTGTGCCTACTGCCTCGGA-3′).
Mice were subsequently intercrossed with CAG-rtTA reverse 
transactivator mice (The Jackson Laboratory) to generate hetero-
zygous double-transgenic (CAG-rtTA+/– TRE-shRNA+/–) mice. Mice 
were backcrossed more than 6 times with C57BL/6JOlaHsd WT mice 
(Envigo). Phd2 single-KD mice carried alleles of CAG-rtTA+/– TRE-
shPhd2#9+/– (shPhd2#9) or CAG-rtTA+/– TRE-shPhd2#3+/– (shPhd2#3). 
Control mice for KD experiments carried a single allele of CAG- 
rtTA but no TRE allele (CAG-rtTA+/– TRE–/–) (control). For double-KD 
mice bearing both Phd2- and Hif1a- or Hif2a-KD alleles, CAG- 
rtTA+/+ TRE-shPhd2#9+/– mice were crossed with CAG-rtTA–/– TRE- 
shHif1a#5+/– or CAG-rtTA–/– TRE-shHif2a#3+/– mice to produce CAG- 
rtTA+/– TRE-shPhd2#9+ TRE-shHif1a#5+ (shPhd2Hif1) or CAG-rtTA+/– 
TRE-shPhd2#9+ TRE-shHif2a#3+ (shPhd2Hif2) mice. To induce shRNA 
expression, shRNA-bearing and control mice were provided ad libitum 
access to drinking water containing 2 mg/mL doxycycline with 30% 
sucrose from the age of 8 to 12 weeks. All of the following KO mouse 
lines were also bred in our facilities: RosaERTCre Phd2fl/fl (Phd2-KO), 
RosaERTCre Phd2fl/fl HIf1afl/fl (Phd2Hif1-KO), RosaERTCre Phd2fl/fl 
HIf2afl/fl (Phd2Hif2-KO), and RosaERTCre– (control) mice and have 
been described before (64). Tissues from KO and control mice were 
harvested 4 weeks after receiving tamoxifen treatment for 1 week 
by oral gavage. All KD and KO mice were housed in the Functional 
Genetics Facility of the Wellcome Trust Centre for Human Genetics 
(University of Oxford, Oxford, United Kingdom) in individually venti-
lated cages, with the only reported positives on health screening over 
the entire time course of these studies being for Helicobacter species 
(spp.), Tritrichomonas spp., and Entamoeba spp. Food and water were 
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entific, 500 μl beads per 2 × 108 cells). After magnetic separation, the 
remaining cells were stained with anti-CD25 phycoerythrin (PE) anti-
body (clone PC61.5, eBioscience; 5 μl/108 of the initial cell number) 
and then with anti-PE microbeads (Miltenyi Biotec; 20 μl/107 CD4+ 
cells). For selection of the CD4+CD25+ component, positive cells were 
isolated by magnetic separation using the MACS system (Miltenyi Bio-
tec), and the CD4+CD25– effector cells were obtained from the nega-
tive fraction in the cell separation column. On reanalysis, CD4+CD25+ 
cells expressed Foxp3 to a purity of more than 85%.
BMT. BM was harvested from 8- to 12-week-old shPhd2#9 or 
control donors (both CD45.2 and C57BL/6 backgrounds) by flushing 
tibiae and femurs with PBS (Gibco BRL, Thermo Fisher Scientific) 
supplemented with 2% BSA (MilliporeSigma). Single-cell suspen-
sions, minus settled aggregates, were washed once with PBS and BSA 
through a 70-μm nylon cell strainer (Falcon). Treated recipient mice 
(CD45.1 and C57BL/6) received a split lethal dose of 4.5 plus 4.5 Gy 
total body irradiation (TBI) followed by intravenous injection of 5 × 
106 BM cells. Antibiotic prophylaxis with co-trimoxazole in the drink-
ing water was provided to mice before and immediately after trans-
plantation. Mice were monitored by serial flow cytometric analysis of 
the peripheral blood. Eight weeks after irradiation and transplanta-
tion, cohorts of mice were started on doxycycline treatment.
Skin transplantation. CBA (CBA, H-2k), C57BL/6 (B6, H-2b), and 
C57BL/6 Rag 1−/− (H-2b) mice were obtained from and housed in the 
Biomedical Services Unit of the John Radcliffe Hospital (Oxford, Unit-
ed Kingdom) in individually ventilated cages, with the only report-
ed positives on health screening over the entire time course of these 
studies being for Helicobacter spp., occasional mouse norovirus, and 
Tritrichomonas spp. Food and water were provided ad libitum, and the 
animals were maintained on a 12-hour light/12-hour dark cycle. Mice 
were randomized and groups split across cages. All scoring was done 
in a blinded fashion, and no animals were excluded from the study. 
Sex-matched mice between 6 and 12 weeks of age at the time of the 
first experimental procedure were used in all experiments. T cell–defi-
cient (C57BL/6 Rag1−/−) mice were reconstituted intravenously with 
1 × 104 CD4+CD25– effector cells from C57BL/6 mice with or without 
1 × 104 to 5 × 104 CD4+CD25+ cells from WT C57BL/6, shPhd2#9, or 
control animals. The day after reconstitution, the mice received a CBA 
skin graft under general anesthesia. Full-thickness tail skin was trans-
planted into graft beds on the flanks of recipient mice (67). Grafts were 
then monitored daily, and graft rejection was defined by complete 
destruction of the skin.
In vitro suppression assays. Sample processing, cell isolation, and in 
vitro T cell analyses were performed by the Transplantation Research 
Immunology Group following established laboratory protocols. Assay 
performance and data reporting conformed with the Minimal Infor-
mation About T cell Assays (MIATA) guidelines (68) and the Mini-
mum Information about Tregs (MITREG) guidelines (69). For in vitro 
suppression assays, splenocytes from shPhd2#9 or control C57BL/6 
(H-2b) mice pretreated with doxycycline in the water for 4 weeks were 
used as a source of CD4+CD25+ cells. CD4+CD25+ cells and effec-
tor T cells (Teffs) (CD4+CD25–) were isolated using a Dynabeads 
Untouched Mouse CD4 Cells Kit (catalog 11415D, Invitrogen, Ther-
mo Fisher Scientific) followed by CD25+ cell enrichment using an 
anti–CD25-PE antibody (clone PC61.5, eBioscience, Thermo Fisher 
Scientific) and anti-PE microbeads (catalog 130-048-801, Miltenyi 
Biotec). Cells were counted using trypan blue staining, a hemocy-
(NB100-122, Novus Biologicals); PHD3 (produced in-house) (66); 
and β-actin (ab49900, Abcam), followed by HRP-conjugated sec-
ondary antibodies. Conversion of the chemiluminescent substrate 
was measured on an image scanner (ChemiDoc XRS+ System with 
Image Lab Software, Bio-Rad Laboratories).
For FACS flow cytometric analysis, single-cell suspensions were 
prepared from pLNs (subiliac and axillary), spleen, and femoral BM 
in FACS buffer (PBS, pH 7.4, 1% BSA). Following RBC lysis, cells were 
stained with antibodies according to the manufacturer’s protocol. Cell 
preparations were stained with 7-AAD (eBioscience, Thermo Fisher 
Scientific), and only live cells were analyzed. After washing, cells were 
measured using a BD FACSCanto II (BD Biosciences) and analyzed 
using BD FACS DIVA and FlowJo software (TreeStar). For intracel-
lular Foxp3 measurement, cells were fixed and permeabilized using 
a Foxp3 staining kit (eBioscience, Thermo Fisher Scientific) before 
staining for Foxp3, according to the manufacturer’s protocol. The fol-
lowing antibodies were used for flow cytometric analysis: CD3 (clone 
145-2C11, eBioscience); CD3 (clone 17A2, ebioscience); CD4 (clone 
GK1.5, eBioscience); CD8 (clone 53-6.7, eBioscience); B220 (clone 
30-H12, eBioscience); CD45 (clone 30-F11, eBioscience); CD19 (clone 
9B1, eBioscience); Gr-1 (clone RB6-8C5, eBioscience); CD25 (clone 
PC61, eBioscience); CD25 (clone PC61, BD Biosciences); Foxp3 (clone 
30-F11, eBioscience); Foxp3 (clone FJK-16s, eBioscience); CD62L 
(clone MEL-14; BD Biosciences); CD44 (clone IM7, BioLegend); 
IL-17A (clone ebio17B7, eBioscience); IL-4 (clone BVD6-24G2, eBio-
science); IFN-γ (clone XMG1.2, eBioscience); IL-2 (clone JES6-5H4, 
eBioscience); TNF-α (clone MP6-XT22, eBioscience); IL-10 (clone 
JES5-16E3, eBioscience); GATA-3 (clone L50-823, BD Biosciences); 
T-bet (clone ebio4b10, eBioscience); and ROR-γt (clone AFKJS-9, 
eBioscience). The secretion of IL-17A, IL-4, IFN-γ, IL-2, TNF-α, and 
IL-10 was determined by flow cytometry after a 5-hour stimulation 
with 1 μg/mL ionomycin (catalog 56092-82-1, MilliporeSigma), 100 
ng/mL PMA (catalog P1585, MilliporeSigma), and 5 μg/mL brefeldin 
A (catalog 420601, BioLegend). Gating strategies are shown in Sup-
plemental Figure 4.
Histology. Organ samples were fixed in fresh 10% neutral buff-
ered formalin (MilliporeSigma) overnight and further subjected to 
routine histological procedures for embedment in paraffin. Sections 
(4-μm-thick) from at least 2 or 3 different animals per group were 
placed on slides adjacent to each other to enable cross-comparison 
within a slide after H&E staining. Whole tissue sections were scanned 
at ×400 magnification using a NanoZoomer S210 digital slide scanner 
and reviewed using NDP.view2 software (both from Hamamatsu Pho-
tonics). Tissues were initially analyzed and scored in a blinded fash-
ion by an independent mouse histopathologist; representative images 
were subsequently chosen to illustrate key histological findings.
Cell purification for adoptive transfer. CD4+CD25+ and CD4+CD25– 
cells were isolated using the Miltenyi MACS system (Miltenyi Biotec) 
as previously described (45). Single-cell suspensions were prepared 
from LNs and spleens of 8- to 12-week-old shPhd2#9, control, and WT 
C57BL/6 mice, red cells were lysed, and cells were resuspended in 
PBS plus 1% FBS. Cells (2 × 108) were then stained with rat anti-mouse 
antibodies against CD8 (clone YTS 169, 80 μg); B220 (clone RA3-6B2, 
100 μg); MHC class II (clone TIB 120, 100 μg); and Mac-1 (M1-70, 100 
μg) (antibodies produced and purified from their respective hybrid-
omas in-house) followed by magnetic negative depletion using sheep 
anti–rat IgG–coated Dynabeads (Dynal Biotech, Thermo Fisher Sci-
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authors. Figures were prepared by AY, PSM, and K. Kawai, with 
input from the other authors. The following authors made com-
parable contributions: AY initiated the experimental work and 
remained involved throughout; JH contributed essential immu-
nological expertise in defining the immunological phenotype; AY 
is named first, because his contributions were made over a longer 
period than those of JH; joint senior authors PJR and CWP ini-
tiated the project; CWP managed the project throughout; and FI 
contributed essential immunological expertise.
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